United States · Growth startup

Who invested in Bluesight

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

HealthcareSoftware

Funding summaryUpdated 26 Oct 2026

Undisclosedraised across 1 round since 2023, from 1 source

Latest round
GrowthJul 2023
Led by
Thoma Bravo
Investors
5 (1 led)
See who backed them

The rounds

  1. Jul 2023

Founders and team

From Bluesight's own website: 1 founder, 7 on the team.

Kevin MacDonaldCo-Founder and CEO
  • Jason Vander MeerChief Product Officer
  • Mark PetersChief Financial Officer
  • Matt McAluneyChief Revenue Officer
  • Vijay VenkateshChief Technology Officer
  • Amy SchartnerVP, People
  • Jacki McLainVP of Sales
  • Wayne ChanVP of Legal

Everyone who backed them

Thoma BravoPrivate equity1round, led 1
Kleiner PerkinsVC firm1round
Mayo ClinicInvestment firm1round
Sands Capital VenturesPrivate equity1round
New Leaf VenturesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Bluesight

Who invested in Bluesight?

Bluesight's investors include Thoma Bravo, Kleiner Perkins, Mayo Clinic, Sands Capital Ventures and New Leaf Ventures. Thoma Bravo led its latest round.

How much has Bluesight raised?

Bluesight has raised 1 round since 2023, none with a disclosed amount.

When did Bluesight last raise?

Bluesight's most recent round was a Growth in Jul 2023, led by Thoma Bravo.

Who backed Bluesight first?

Bluesight's first round on record, in Jul 2023, was backed by Thoma Bravo, Kleiner Perkins and Mayo Clinic and 2 others.

What stage is Bluesight at?

Bluesight's latest named round is a Growth, in Jul 2023.

Where is Bluesight based?

Bluesight is based in the United States.

Who led Bluesight's rounds?

Thoma Bravo led the Growth in 2023.

Companies like Bluesight

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.